A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: engaged (185), occupied (51), unavailable (47)

Finance and Performance Reports 2023-24 Month 2 May 2023

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 2 9.2 Ian Howard – Ch
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-2-May-2023.pdf

Guide to the Mental Capacity Act - patient information

Description
This leaflet provides an overview of the Mental Capacity Act 2005.
Url
/Media/UHS-website-2019/Patientinformation/Visitinghospital/Guide-to-the-Mental-Capacity-Act-2865-PIL.pdf

Botox injections for axillary hyperhidrosis - patient information

Description
This factsheet contains information about having Botox (botulinum toxin) injections for axillary hyperhidrosis (excessive sweating).
Url
/Media/UHS-website-2019/Patientinformation/Skin/Botox-injections-for-axillary-hyperhidrosis-2004-PIL.pdf

Transoesophageal echocardiogram (TOE) - patient information

Description
This factsheet provides information about having a transoesophageal echocardiogram.
Url
/Media/UHS-website-2019/Patientinformation/Heartandlungs/Transoesophageal-echocardiogram-TOE-638-PIL.pdf

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) T
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

Acute kidney injury - patient information

Description
We have written this factsheet to provide you with information about acute kidney injury (AKI).
Url
/Media/UHS-website-2019/Patientinformation/Generalmedicine/Acute-kidney-injury-1090-PIL.pdf

Remuneration and Appointment Committee ToR Feb 2023

Description
Remuneration and Appointment Committee Terms of Reference Date Issued: 28 February 2023 Review Date: February 2024 Documen
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Remuneration-and-Appointment-Committee-ToR-Feb-2023.pdf

Axicel-Cyclophosphamide(500)-Fludarabine(30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Axicel-Cyclophosphamide500-Fludarabine30.pdf

Finance and Performance Reports 2020-21 Month 4 July 2020

Description
2020/21 Finance Report - Month 4 Report to: Board of Directors and Finance & Investment Committee August
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/finance-and-performance-reports-2020-21-month-4-july-2020-1.pdf

InP-LEAM

Description
Chemotherapy Protocol LYMPHOMA LOMUSTINE-CYTARABINE-ETOPOSIDE (split)-MELPHALAN (LEAM) Inpatient Regimen Regimen Lymphoma – InP-LEA
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-LEAM.pdf
741 to 750 of 1000
Previous … 73 74 75 76 77 … Next